Preoteasa D, Mocanu C
Oftalmologia. 2001;54(4):20-31.
The primary objective of this prospective study was to evaluate the efficacy of lowering intraocular pressure, safety and tolerability of Brinzolamide 1% ophthalmic suspension as primary or adjunctive therapy in hypertensive glaucomas.
Brinzolamide 1% was administrated in monotherapy or in combination for 26 patients suffering from hypertensive glaucomas. The patients were divided in two groups: group I--included 10 patients (20 eyes) with primary open-angle glaucoma in which suspension Brinzolamide was administrated in monotherapy, and, group II--(16 patients with 30 eyes) with diverse forms of hypertensive glaucomas, that the Brinzolamide was administrated in adjunctive therapy, after the failure of another forms of medication, especially, beta-blockers. Intraocular pressure was assessed at 8, 10 AM, and 6 PM in first day, then daily at 8 AM, 7 days, and finally, weekly, at 8 AM all the period. Dilated fundoscopy, automated perimetry, visual acuity, were performed in addition to hematology, blood chemistry, urinalysis testing and ocular events.
The intraocular pressure-lowering observed on treatment was as follows: 3.5 mmHg to 4.8 mmHg (13.5% to 18.2%) in patients which Brinzolamide 1% dosed two times a day, and, 4.2 to 5.2 mmHg (17.8 to 20.9%) after administration Brinzolamide three times a day. The association of Brinzolamide with another therapy induces in an additive ocular hypotensive effect, which was stable in the whole period of the study. The ocular and general tolerance was significantly improved for another hypotensive drugs and another carbonic anhydrase inhibitors topically active. This fact allows a long treatment period.
